Literature DB >> 1450049

Multicenter phase II trial of brequinar sodium in patients with advanced melanoma.

R Natale1, R Wheeler, M Moore, B Dallaire, W Lynch, R Carlson, A Grillo-Lopez, J Gyves.   

Abstract

Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously. In 14 patients evaluable for efficacy, there were no objective responses. The toxicity was moderate. We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1450049     DOI： 10.1093/oxfordjournals.annonc.a058298

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  12 in total

1.  The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.

Authors:  David B Sykes
Journal:  Expert Opin Ther Targets       Date:  2018-10-17       Impact factor: 6.902

2.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

Review 3.  Human pyrimidine nucleotide biosynthesis as a target for antiviral chemotherapy.

Authors:  Ayse Okesli; Chaitan Khosla; Michael C Bassik
Journal:  Curr Opin Biotechnol       Date:  2017-04-27       Impact factor: 9.740

4.  Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.

Authors:  Salvatore Galati; Stefano Sainas; Marta Giorgis; Donatella Boschi; Marco L Lolli; Gabriella Ortore; Giulio Poli; Tiziano Tuccinardi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

5.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 6.  DHODH and cancer: promising prospects to be explored.

Authors:  Yue Zhou; Lei Tao; Xia Zhou; Zeping Zuo; Jin Gong; Xiaocong Liu; Yang Zhou; Chunqi Liu; Na Sang; Huan Liu; Jiao Zou; Kun Gou; Xiaowei Yang; Yinglan Zhao
Journal:  Cancer Metab       Date:  2021-05-10

7.  Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).

Authors:  Marianne Lucas-Hourani; Hélène Munier-Lehmann; Farah El Mazouni; Nicholas A Malmquist; Jane Harpon; Eloi P Coutant; Sandrine Guillou; Olivier Helynck; Anne Noel; Artur Scherf; Margaret A Phillips; Frédéric Tangy; Pierre-Olivier Vidalain; Yves L Janin
Journal:  J Med Chem       Date:  2015-06-30       Impact factor: 7.446

8.  Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.

Authors:  Joseph T Madak; Christine R Cuthbertson; Yoshinari Miyata; Shuzo Tamura; Elyse M Petrunak; Jeanne A Stuckey; Yanyan Han; Miao He; Duxin Sun; Hollis D Showalter; Nouri Neamati
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

Review 9.  Small molecule activators of the p53 response.

Authors:  Marcus J G W Ladds; Sonia Laín
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

10.  A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells.

Authors:  Hossam Kamli; Gaffar S Zaman; Ahmad Shaikh; Abdullah A Mobarki; Prasanna Rajagopalan
Journal:  Oncol Res       Date:  2021-08-05       Impact factor: 5.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.